{"id":5479,"date":"2026-01-17T01:06:28","date_gmt":"2026-01-16T22:06:28","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5479"},"modified":"2026-01-17T01:06:30","modified_gmt":"2026-01-16T22:06:30","slug":"atossa-therapeutics-receives-fda-orphan-drug-designation-for-z-endoxifen-for-the-treatment-of-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/atossa-therapeutics-receives-fda-orphan-drug-designation-for-z-endoxifen-for-the-treatment-of-duchenne-muscular-dystrophy\/","title":{"rendered":"Atossa Therapeutics recibe la designaci\u00f3n de f\u00e1rmaco hu\u00e9rfano FDA para (Z)-Endoxifen para el tratamiento de la distrofia muscular de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Atossa Therapeutics, anunci\u00f3 que la Oficina de Desarrollo de Productos Hu\u00e9rfanos de la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos (\u201cFDA\u201d) ha otorgado la designaci\u00f3n de medicamento hu\u00e9rfano a (Z)-endoxifen para el tratamiento de la distrofia muscular de Duchenne (\u201cDMD\u201d). &gt;&gt; <strong>M\u00e1s informaci\u00f3n:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/es\/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/dmdwarrior.com\/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-for-duchenne-muscular-dystrophy\/\" rel=\"noreferrer noopener\">Atossa Therapeutics recibe la designaci\u00f3n de enfermedad pedi\u00e1trica rara FDA para (Z)-Endoxifen<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cAdem\u00e1s de la designaci\u00f3n de Enfermedad Pedi\u00e1trica Rara recibida previamente, la Designaci\u00f3n de Medicamento Hu\u00e9rfano para (Z)-endoxifen en la distrofia muscular de Duchenne es un hito importante para Atossa a medida que avanzamos en el desarrollo de (Z)-endoxifen para esta enfermedad grave y debilitante\u201d, se\u00f1al\u00f3 Steven C. Quay, MD, Ph.D., Presidente y Director Ejecutivo de Atossa Therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Atossa planea seguir colaborando con FDA a medida que avanza en los esfuerzos de desarrollo y proporcionar\u00e1 actualizaciones seg\u00fan corresponda.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sigue esta p\u00e1gina<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/es\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Todos los ensayos cl\u00ednicos para la distrofia muscular de Duchenne<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Atossa Therapeutics, announced that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) Office of Orphan Products Development has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy (&#8220;DMD&#8221;). >> Learn More: Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen &#8220;In addition to the previously received Rare Pediatric Disease designation, Orphan [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5480,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[461,462,464,463],"class_list":["post-5479","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-z-endoxifen","tag-atossa-therapeutics","tag-endoxifen","tag-tamoxifen"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/5479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=5479"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/5479\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/5480"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=5479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=5479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=5479"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}